Compare UTF & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTF | IDYA |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 2004 | 2019 |
| Metric | UTF | IDYA |
|---|---|---|
| Price | $27.00 | $31.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $52.86 |
| AVG Volume (30 Days) | 290.5K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $218,710,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $201.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $23.42 | $20.50 |
| 52 Week High | $27.65 | $39.28 |
| Indicator | UTF | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 48.91 | 58.29 |
| Support Level | $26.54 | $29.51 |
| Resistance Level | $27.23 | $31.51 |
| Average True Range (ATR) | 0.33 | 1.66 |
| MACD | -0.00 | 0.33 |
| Stochastic Oscillator | 36.44 | 79.93 |
Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. Under normal market conditions, the fund invests the majority of its managed assets in securities issued by infrastructure companies, which consist of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.